National Bank of Canada
INDP icon

National Bank of Canada’s Indaptus Therapeutics INDP Stock Holding History

National Bank of Canada’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18
Closed -$1K – 2781
2022
Q2 		$1K Hold
18
– – ﹤0.01% 2690
2022
Q1 		$2K Hold
18
– – ﹤0.01% 2699
2021
Q4 		$3K Buy
+18
New +$3.34K ﹤0.01% 2623

Other funds holding INDP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $670M AUM 34.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

National Bank of Canada's INDP Position: Q3 2022 in Review

National Bank of Canada sold out of Indaptus Therapeutics (INDP) in Q3 2022, closing a stake of 18 shares — an estimated $1K sold.

National Bank of Canada first reported a position in INDP in Q4 2021 and held it in 3 quarters. The position peaked at $3K in Q4 2021. 17 funds tracked by Wall St. Rank hold INDP as of Q3 2022.

  • National Bank of Canada reported no remaining Indaptus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • National Bank of Canada sold 18 Indaptus Therapeutics shares in Q3 2022, an estimated $1K.
  • National Bank of Canada first reported a position in Indaptus Therapeutics in Q4 2021 and held it in 3 quarters.
  • National Bank of Canada's Indaptus Therapeutics position peaked at $3K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2022.

Based on National Bank of Canada's 13F filing for Q3 2022, filed 13 Oct 2022.